|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
|
|
| The Next Generation Trial: Assessing 18F-PSMA-1007 PET and MRI in Primary Staging of Prostate Cancer Patients
|
| Nikhile Mookerji, MD
|
| Nikhile Mookerji presented findings from a trial assessing 18F-PSMA-1007 PET and MRI in the primary staging of prostate cancer patients at the AUA 2024 meeting. The study aimed to determine whether 18F-PSMA-1007 PET/CT is superior to multiparametric MRI in locoregional staging. Results showed that 18F-PSMA-1007 PET/CT outperformed MRI in correctly identifying the prostate cancer T stage, dominant nodule, laterality, extracapsular extension, and seminal vesical invasion.
|
|
|
|
|
|
| PSMAfore: Efficacy of 177Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI
|
| Xiao Wei, MD, MA
|
| Xiao Wei presented findings from the PSMAfore trial at the AUA 2024 meeting, focusing on the efficacy of 177Lu-PSMA-617 versus androgen receptor pathway inhibitor (ARPI) change in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). The trial demonstrated that 177Lu-PSMA-617 significantly prolonged radiographic progression-free survival compared to ARPI change, regardless of pre-randomization ARPI treatment.
|
|
|
|
|
|
| Prostate Cancer: Staging I
|
|
| PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients |
| Rashid Sayyid, MD, MSc |
| Rashid Sayyid presented findings on PSMA PET/CT-detected mesorectal nodal metastasis in biochemically recurrent prostate cancer patients. Approximately 11% of patients undergoing 18F-DCFPyL-PET/CT scanning had mesorectal lymph node metastasis, with pT3b disease significantly associated with increased odds. The study suggests alternative drainage routes for prostate cancer cells and emphasizes the need for further research to define prognosis and treatment implications for patients with mesorectal lymph node involvement. |
|
|
|
|
|
| Comparison of 68-Ga-PSMA PET/CT and Multiparametric MRI in Detecting Lymph Node Metastases in Patients with Intermediate or High-Risk Prostate Cancer |
| Sanjay Kumar MD |
| Sanjay Kumar presented findings on a prospective comparative study of 68Ga-PSMA PET/CT and mpMRI in detecting lymph node metastases in intermediate or high-risk prostate cancer patients. The study, which enrolled 92 potential candidates for radical prostatectomy, showed that 68Ga-PSMA PET/CT exhibited higher sensitivity, specificity, negative predictive value, positive predictive value, and accuracy compared to mpMRI for detecting lymph node metastasis. These results suggest that 68Ga-PSMA PET/CT may be superior to mpMRI in this context. |
|
|
|
|
|
| Descriptive Tumor Characteristics of 992 Consecutive Patients Who Underwent Staging with PSMA PET/CT Before Radical Prostatectomy.
|
| Felix Preisser, MD
|
| Felix Preisser presented findings on a retrospective cohort of 992 patients who underwent radical prostatectomy and had a PSMA PET/CT prior to surgery at the 2024 AUA Annual Meeting. Among the patients, 80.8% had miN0M0 disease, 11.3% had miN1 disease, and 7.9% had miM1 disease. Those with miM1 and miN1 disease exhibited more unfavorable pathologic characteristics, including higher PSA levels and a higher frequency of D’Amico high-risk criteria, advanced disease stage, and aggressive tumor grade, compared to miN0M0 patients.
|
|
|
|
|
|
|
|
|
|
|
| Correlation of Intraprostatic SUVmax During PSMA PET/CT and Adverse Pathology at Radical Prostatectomy
|
| Felix Preisser, MD
|
| Felix Preisser presented findings on the correlation between intraprostatic maximum standardized uptake value (SUVmax) during PSMA PET/CT and adverse pathology at radical prostatectomy (RP) at the 2024 AUA Annual Meeting. Their retrospective study included 544 patients with intermediate and high-risk prostate cancer. They found that SUVmax ≥9.5 on PSMA PET/CT was independently associated with adverse pathology and non-organ-confined disease at RP.
|
|
|
|
|
|
| Development of a Novel Risk Stratification for Prostate Cancer Patients Candidate to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging |
| Francesco Barletta, MD |
| Francesco Barletta presented a novel risk stratification model for prostate cancer patients undergoing radical prostatectomy (RP) and preoperative PSMA-PET staging at the 2024 AUA Annual Meeting. This model, based on retrospective data from 707 patients across Europe, categorized patients into intermediate, high, or very high risk groups. The inclusion of PSMA-PET data improved the prediction of early biochemical failure (BCF) after RP, demonstrating superior discrimination compared to existing risk classifications. |
|
|
|
|
|
| Predicting Positive 68Ga-PSMA PET/CT Scans in Biochemical Recurrence Following Prostatectomy. |
| Maya Ataya, MD |
| Maya Ataya presented findings at the 2024 AUA Annual Meeting regarding predictors of positive 68Ga-PSMA PET/CT scans in patients experiencing biochemical recurrence (BCR) after radical prostatectomy (RP). Their retrospective study identified factors associated with positive scans, revealing that PSA value ≥0.2 and ISUP grade ≥3 were significant predictors. These findings emphasize the potential of PSMA-PET as an effective imaging modality in detecting disease recurrence post-RP. |
|
|
|
|
|
| Prostate Cancer: Detection & Screening I |
| Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men |
| Giuseppe Chiarelli, MD |
| Giuseppe Chiarelli presented findings at the 2024 AUA Annual Meeting, analyzing midlife baseline PSA as a predictor of lethal prostate cancer in Black and White men. Their study, conducted at the Henry Ford Health system, included over 112,000 men aged 40–59. Results showed that Black men faced a significantly higher risk of developing lethal prostate cancer compared to White men, even with similar midlife baseline PSA levels. |
|
|
|
|
|
| Characteristics of PI-RADS 5 Lesions with a Negative or Gleason Grade Group 1 Biopsy |
| Lindsey Webb, BSME |
| Lindsey Webb presented findings on PI-RADS 5 lesions in prostate cancer detection. Their study evaluated pre-biopsy factors associated with benign or low-grade pathology in these lesions, aiming to avoid unnecessary biopsies. Among 838 PI-RADS 5 lesions, 13% were benign, and 18% had Grade Group 1 disease. Factors like inflammation, lesion location, prior negative biopsy, and active surveillance status were associated with decreased odds of clinically significant cancer. |
|
|
|
|
|
| Integrating MR and Ultrasound Images for AI-based Prostate Cancer Detection in Transrectal Ultrasound Images: A Comparative Assessment with Clinicians |
| Hassan Jahanandish, Ph.D. |
| Hassan Jahanandish presented findings on an AI-based approach integrating MRI and ultrasound images for prostate cancer detection in transrectal ultrasound (TRUS) images. Their novel deep learning framework, trained on a dataset of 102 patients, achieved higher sensitivity (80%) and specificity (70%) compared to expert clinicians (35% sensitivity, 92% specificity), indicating its potential to enhance biopsy diagnosis without the need for pre-biopsy prostate MRI. |
|
|
|
|
|
| International Prostate Forum |
| Updates in Prevention, Diagnostics and Surgery: PSMA PET updates |
| Adam Weiner, MD |
| Adam Weiner provided updates on the applications of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in prostate cancer at AUA 2024. He highlighted the efficacy of PSMA-PET/CT in various diagnostic and staging scenarios, including its ability to enhance sensitivity and negative predictive value in combination with multiparametric MRI (mpMRI) for detecting clinically significant prostate cancer. |
|
|
|
|
|
